Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)-Reference-Cited by-同舟云学术

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)

Published:2018-02-23 Issue:3 Volume:178 Page:674-681
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Papp K.A.¹^ORCID,Leonardi C.L.²,Blauvelt A.³^ORCID,Reich K.⁴^ORCID,Korman N.J.⁵,Ohtsuki M.⁶,Paul C.⁷^ORCID,Ball S.⁸,Cameron G.S.⁸,Erickson J.⁸,Zhang L.⁸,Mallbris L.⁸,Griffiths C.E.M.⁹

Affiliation:

1. K Papp Clinical Research and Probity Medical Research Inc.; Waterloo ON Canada

2. Saint Louis University; St Louis MO U.S.A.

3. Oregon Medical Research Center; Portland OR U.S.A.

4. Dermatologikum Hamburg and SCIderm GmbH; Hamburg Germany

5. Case Western Reserve University School of Medicine; Cleveland OH U.S.A.

6. Department of Dermatology; Jichi Medical University; Tochigi Japan

7. Department of Dermatology; Paul Sabatier University; Toulouse France

8. Eli Lilly and Company; Indianapolis IN U.S.A.

9. Dermatology Centre; Salford Royal NHS Foundation Trust; University of Manchester; Manchester Academic Health Science Centre; Manchester U.K.

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjd.16050/fullpdf

Reference23 articles.

1. Psoriasis;Di Meglio;Cold Spring Harb Perspect Med,2014

2. Immunology of psoriasis;Lowes;Annu Rev Immunol,2014

3. Global epidemiology of psoriasis: a systematic review of incidence and prevalence;Parisi;J Invest Dermatol,2013

4. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis;Chandran;J Autoimmun,2010

5. Biologics for psoriasis;Dubin;Nat Rev Drug Discov,2003

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studies;Expert Opinion on Drug Safety;2024-09-12

2. Treatment of Nail Psoriasis;Dermatologic Clinics;2024-07

3. Biologika als „game changer“;Deutsche Dermatologie;2024-07

4. Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis);Dermatology and Therapy;2024-05-15

5. Advantages of IL-17 inhibitor, ixekizumab, in the treatment of severe psoriasis;Meditsinskiy sovet = Medical Council;2024-03-08